|
|
||||||||
From the Department of Neurology (Drs. Soininen, Helkala, and Riekkinen), University Central Hospital of Kuopio, Harjamaki Mental Hospital (Dr. Koskinen), Kuopio, Finland, and Organon (Dr. Pigache), Oss, The Netherlands.
The synthetic ACTH 49 analog, Org 2766, was administered to 77 Alzheimer's patients for 6 months in a double-blind, placebo-controlled study. Although Org 2766 was tolerated well, no significant effect of Org 2766 could be demonstrated in terms of rating scales or cognitive functions.
Address correspondence and reprint requests to Dr. Soininen, Department of Neurology, University Central Hospital of Kuopio, SF-70210 Kuopio, Finland.
Accepted for publication January 4, 1985.
This article has been cited by other articles:
![]() |
R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, May 8, 2001; 56(9): 1154 - 1166. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Patel Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review J Geriatr Psychiatry Neurol, April 1, 1995; 8(2): 81 - 95. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |